Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C
- PMID: 16448454
- DOI: 10.1111/j.1478-3231.2005.01219.x
Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C
Abstract
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver.
Methods: Ninety-eight patients received subcutaneously 180 mug peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated.
Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi2=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy.
Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
Similar articles
-
Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.Am J Gastroenterol. 2010 Sep;105(9):1970-7. doi: 10.1038/ajg.2010.110. Epub 2010 Mar 16. Am J Gastroenterol. 2010. PMID: 20234345
-
Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.J Clin Gastroenterol. 2010 Nov-Dec;44(10):707-12. doi: 10.1097/MCG.0b013e3181d2ef1a. J Clin Gastroenterol. 2010. PMID: 20195166
-
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.Gut. 2012 Oct;61(10):1473-80. doi: 10.1136/gutjnl-2011-300749. Epub 2012 Mar 2. Gut. 2012. PMID: 22387529 Clinical Trial.
-
[Chronic hepatitis C--patients "difficult to treat"].Przegl Epidemiol. 2006;60(1):109-13. Przegl Epidemiol. 2006. PMID: 16758748 Review. Polish.
-
Management of patients with chronic hepatitis C infection.Clin Exp Med. 2006 Mar;6(1):20-6. doi: 10.1007/s10238-006-0089-4. Clin Exp Med. 2006. PMID: 16550340 Review.
Cited by
-
Evolution of interferon-based therapy for chronic hepatitis C.Hepat Res Treat. 2010;2010:140953. doi: 10.1155/2010/140953. Epub 2010 Oct 10. Hepat Res Treat. 2010. PMID: 21152178 Free PMC article.
-
Predicting the probable outcome of treatment in HCV patients.Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. doi: 10.1177/1756283X09339079. Therap Adv Gastroenterol. 2009. PMID: 21180557 Free PMC article.
-
Intestinal Barrier and Permeability in Health, Obesity and NAFLD.Biomedicines. 2021 Dec 31;10(1):83. doi: 10.3390/biomedicines10010083. Biomedicines. 2021. PMID: 35052763 Free PMC article. Review.
-
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.Infection. 2013 Feb;41(1):21-6. doi: 10.1007/s15010-012-0352-4. Epub 2012 Oct 14. Infection. 2013. PMID: 23065463
-
Managing chronic hepatitis C in the difficult-to-treat patient.Liver Int. 2007 Dec;27(10):1297-310. doi: 10.1111/j.1478-3231.2007.01613.x. Liver Int. 2007. PMID: 18036096 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources